What is Repare Therapeutics?
Repare Therapeutics is a clinical-stage precision oncology company that leverages its proprietary synthetic lethality approach to discover and develop novel therapeutics. The company's genome-wide, CRISPR-enabled SNIPRx® platform is designed to systematically identify and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair mechanisms. This innovative platform positions Repare Therapeutics at the forefront of precision medicine, aiming to deliver tailored treatments for cancer patients based on their specific genetic profiles.
How much funding has Repare Therapeutics raised?
Repare Therapeutics has raised a total of $150.5M across 2 funding rounds:
Series A
$68M
Series B
$82.5M
Series A (2017): $68M with participation from Celgene Switzerland, Versant Ventures, MPM Capital, and Fonds de solidaritu00e9 FTQ
Series B (2019): $82.5M led by Logos Capital, Cowen Healthcare Investments, Fonds de solidarité FTQ, Versant Ventures, MPM Capital, OrbiMed, BVF Partners L.P, Redmile, and BDC Capital
Key Investors in Repare Therapeutics
Versant Ventures
Versant Ventures is a venture capital firm specializing in building and funding innovative biotechnology companies globally. With substantial assets under management, they have a proven track record of successful IPOs and M&A transactions, leveraging extensive experience in venture capital, pharmaceuticals, and biotechnology.
MPM Capital
MPM BioImpact manages venture funds focused on early-stage investments, aiming to convert scientific discoveries into therapeutics for patients. They invest across private and public markets, including a public equities fund.
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. They support companies at various stages of development with a hands-on approach to strategic initiatives and market positioning.
What's next for Repare Therapeutics?
With substantial enterprise-level funding and a recent strategic investment, Repare Therapeutics is well-positioned to advance its pipeline of novel therapeutics. The company's focus on synthetic lethality and its robust SNIPRx® platform suggest a strategic direction towards developing first-in-class treatments for cancers with specific genomic alterations. Future developments will likely involve progressing its clinical candidates through further trials, potentially expanding its therapeutic targets, and forging strategic partnerships to accelerate drug development and commercialization. The significant capital raised indicates a strong investor confidence in the company's scientific approach and its potential to address unmet needs in oncology.
See full Repare Therapeutics company page
